| Entry |
|
|---|
| Name |
Aflibercept (USAN/INN);
Aflibercept (genetical recombination) (JAN);
Ziv-aflibercept;
Eylea (TN);
Zaltrap (TN)
|
|---|
| Product |
|
|---|
| Formula |
C4318H6788N1164O1304S32
|
|---|
| Exact mass |
96837.1694
|
|---|
| Mol weight |
96897.1957
|
|---|
| Sequence |
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS
RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL
VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ
GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH
YTQKSLSLSP G
(Disulfide bridge: 30-79; 124-185; 246-306; 352-410, Dimer: 211; 214) |
|---|
| Type |
Peptide |
|---|
| Remark |
Therapeutic category: ATC code: Product: |
|---|
| Efficacy |
Angiogenesis inhibitor |
|---|
| Disease |
Age-related macular degeneration [DS: H00821] Macular edema [DS: H01651] Diabetic macular edema [DS: H01651] Diabetic retinopathy [DS: H01457] Colorectal cancer [DS: H00020] |
|---|
| Comment |
fusion protein
VEGF-Trap
Inhibitor of aberrant angiogenesis-vascular leak and inflammation, angiogenesis inhibitor for treatment of cancer
|
|---|
| Target |
|
|---|
| Pathway |
| Cytokine-cytokine receptor interaction | | VEGF signaling pathway | | Pathways in cancer |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX44 Aflibercept
D09574 Aflibercept (USAN/INN)
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01L OCULAR VASCULAR DISORDER AGENTS
S01LA Antineovascularisation agents
S01LA05 Aflibercept
D09574 Aflibercept (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1319 Others
D09574 Aflibercept (USAN/INN); Aflibercept (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cytokines
PDGF family
PGF
Aflibercept
D09574 Aflibercept (USAN/INN)
VEGFA
Aflibercept
D09574 Aflibercept (USAN/INN)
VEGFB
Aflibercept
D09574 Aflibercept (USAN/INN)
Antineoplastics [br08340.html]
D09574
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D09574
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09574
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09574
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09574
 |
|---|
| Other DBs |
|
|---|
